AVXS - AveXis, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
102.91
-14.59 (-12.42%)
As of 2:30PM EST. Market open.
Stock chart is not supported by your current browser
Previous close117.50
Open112.50
Bid102.62 x 100
Ask102.79 x 200
Day's range101.40 - 119.00
52-week range50.56 - 119.00
Volume816,708
Avg. volume366,819
Market cap3.291B
BetaN/A
PE ratio (TTM)N/A
EPS (TTM)-5.61
Earnings date14 Mar 2018 - 19 Mar 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est115.80
Trade prices are not sourced from all markets
  • MarketWatch4 hours ago

    AveXis shares drop 6% on company's plans to offer up to $400 mln shares in public offering

    AveXis Inc. shares dropped 6.4% in moderate morning trade Tuesday after the company announced plans for an up to $400 million secondary offering. AveXis also plans to grant the underwriters -- joint book-running ...

  • Globe Newswire7 hours ago

    AveXis Announces Proposed Public Offering of Common Stock

    AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, up to $400 million of shares of its common stock in an underwritten public offering.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Goldman Sachs & Co. LLC, Jefferies LLC and BofA Merrill Lynch are acting as joint book-running managers.  BMO Capital Markets Corp. is acting as lead manager.  AveXis intends to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock at the public offering price, less the underwriting discounts and commissions.

  • Avexis Joins Rank Of Stocks With RS Ratings Over 90
    Investor's Business Daily7 days ago

    Avexis Joins Rank Of Stocks With RS Ratings Over 90

    Avexis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

  • Barrons.com8 days ago

    The Biggest Loser: Biogen Slides 3.7%

    Biogen (BIIB) slipped to the bottom of the S&P 500 on Monday, following disappointing drug results from a competitor late Friday. Biogen lost $12.84, or 3.7%, to $321.65, while the S&P 500 gained 4.56 ...

  • Barrons.com8 days ago

    [$$] Gene-Therapy Update: Mixed Results Don't Dim Hopes

    Three companies developing replacement gene-therapy treatments provided updates last week on clinical trials. Investors were happy with the news at Audentes Therapeutics (BOLD), and disappointed with what they heard from Avexis (AVXS) and Regenxbio (RGNX). Replacement gene therapy has become one of the hottest areas of biotechnology in the past year because of optimism that one-time treatments aimed at replacing faulty genes with healthy ones could result in cures for a host of serious genetic diseases.

  • Globe Newswire8 days ago

    REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy

    REGENXBIO Inc. (Nasdaq:RGNX) and AveXis, Inc. (Nasdaq:AVXS) today announced that they have entered into an amendment which expands upon the exclusive, worldwide license agreement they entered into in March 2014 (2014 License Agreement) for the development and commercialization of products to treat spinal muscular atrophy (SMA). AveXis’ initial proprietary gene therapy candidate, AVXS-101, is in a pivotal trial for the treatment of SMA Type 1, and a Phase 1 trial for SMA Type 2.

  • Biogen Unlikely To See Spinraza Rival In 2018 As AveXis Delayed
    Investor's Business Daily11 days ago

    Biogen Unlikely To See Spinraza Rival In 2018 As AveXis Delayed

    Biogen and Ionis are unlikely to see a competitor to Spinraza in 2018, as rival AveXis faces a significant delay for its competing drug.

  • MarketWatch12 days ago

    AveXis shares down more than 7% after FDA news

    Shares of AveXis Inc. fell more than 7% late Thursday after the gene-therapy company said it was preparing to respond to Food and Drug Administration information requests about AveXis's primary gene therapy, ...

  • Globe Newswire12 days ago

    REGENXBIO Provides Year-End 2017 Corporate Update

    - Initiated third cohort dosing of RGX-314 Phase I clinical trial for wet AMD - - Initiated second cohort dosing of RGX-501 Phase I/II clinical trial for HoFH - - Anticipate completing dosing and presenting topline data from RGX-314 and RGX-501 trials in late 2018 - - Anticipate initiating dosing in clinical trials for MPS I and MPS II in first half 2018 - - Ended 2017 with greater than $175 million in cash, cash equivalents and marketable securities -

  • Globe Newswire12 days ago

    AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1

    AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today provided an update following the receipt of minutes from the end-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) conducted on December 5, 2017, regarding the company’s primary gene therapy candidate, AVXS-101, for the treatment of spinal muscular atrophy (SMA) Type 1. The goal of the end-of-Phase 1 meeting was to review the non-clinical, clinical and Chemistry, Manufacturing and Controls (CMC) data that has been generated by AveXis to date, and to align with the FDA on next steps leading to a Biologics License Application (BLA) submission. The FDA provided detailed information requests in each of the areas discussed, which the company plans to address by submitting the requested information to the investigational new drug (IND) application on an on-going basis.

  • MarketWatch13 days ago

    AveXis could be lifted by rival Spark Therapeutics' pricing scheme for gene therapy: RBC

    Biotech AveXis Inc. could benefit, if indirectly, from payment arrangements set up by rival Spark Therapeutics Inc. for its $850,000-a-patient gene therapy Luxturna, RBC Capital Markets analyst Brian Abrahams ...

  • Biogen, Ionis Sink As Competitor Plans Rival Drug To Spinraza
    Investor's Business Dailylast month

    Biogen, Ionis Sink As Competitor Plans Rival Drug To Spinraza

    Biogen and Ionis sank after AveXis said it would start trials for a new spinal muscular atrophy treatment.

  • Avexis Shows Market Leadership With Jump To 93 RS Rating
    Investor's Business Dailylast month

    Avexis Shows Market Leadership With Jump To 93 RS Rating

    A Relative Strength Rating upgrade for Avexis shows improving technical performance.

  • Why AveXis (AVXS) Could Be Positioned for a Slump
    Zackslast month

    Why AveXis (AVXS) Could Be Positioned for a Slump

    AveXis (AVXS) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

  • Puma Biotechnology Flops Despite Topping Sales, Loss Expectations
    Investor's Business Daily2 months ago

    Puma Biotechnology Flops Despite Topping Sales, Loss Expectations

    Puma Biotechnology reported adjusted losses of $1.36 per share on revenue of $6.1 million.

  • Associated Press2 months ago

    AveXis reports 3Q loss

    On a per-share basis, the Bannockburn, Illinois-based company said it had a loss of $1.52. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...

  • Business Wire2 months ago

    AveXis Announces New England Journal of Medicine Publication of Phase 1 Data of AVXS-101 Gene Replacement Therapy in Spinal Muscular Atrophy Type 1

    AveXis, Inc. , a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, announced data as of August 7, 2017, from the Phase 1 trial of AVXS-101 in patients with spinal muscular atrophy Type 1 were published today in the New England Journal of Medicine in a paper titled “Single-Dose Gene-Replacement Therapy for Spinal ...

  • AveXis Flies, But PTC Sinks On Spinal Muscular Atrophy Data
    Investor's Business Daily3 months ago

    AveXis Flies, But PTC Sinks On Spinal Muscular Atrophy Data

    AveXis touched a record high Tuesday, but PTC dove by double digits as each biotech presented updates on their spinal muscular atrophy programs.

  • After-hours buzz: AVXS, JBL, & more
    CNBC7 months ago

    After-hours buzz: AVXS, JBL, & more

    These are the stocks posting the largest moves after the bell.

  • Business Wire10 months ago

    PBM Capital Group has completed the sale of a majority interest in Breas Medical Group to Fosun Pharma

    CHARLOTTESVILLE, Va.--(BUSINESSWIRE)-- PBM Capital Group has completed the sale of a majority interest in Breas Medical Group (“Breas”) to Fosun Pharma (“Fosun”), a leading healthcare company in China. ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes